Initially dba sAdvanced Protein Technologies Inc., in 2002 the firm was renamed APT Therapeutics. The organizing principle of the firm has been the deelopment of powerful knowledge-based, computer-aided drug discovery engine to enable speed-up of drug development cycles. Genomics having become a primary driving force of the drug discovery process, APT's protein informatics technology can precisely identifying the correct therapeutic proteins and drug targets. As therapeutic protein candidates are identified, the properties of the proteins can be enhanced to increase the probability of clinical success. Then, APT's protein cheminformatics provides a powerful computational solution for developing and optimizing small molecule drug leads. APT Therapeutics is leveraging its platforms in protein informatics, protein cheminformatics, and protein engineering to develop optimized human apyrases as antiplatelet therapies for acute myocardial infarction, stroke, and transplantation complications. The business strategy is to out-license and/or co-develop the drug candidates with pharma partners. U
